Senisca

Senisca is a pioneering biotech focused on a novel target in the ageing space: dysregulated RNA splicing as a driver of cellular senescence. Leveraging over 15 years of foundational academic research, the company is developing oligonucleotide-based therapeutics designed to reset splicing factor levels and effectively 'rejuvenate' senescent cells. This approach positions Senisca to address the root cause of multiple age-related diseases, moving beyond merely clearing senescent cells. With a seasoned leadership team and a proprietary platform, the company is advancing its pipeline through preclinical development.

Oligonucleotide-based platform targeting dysregulated RNA splicing, a novel hallmark of ageing, to reprogram senescent cells by restoring youthful levels of splicing factors.

Senisca competes in the broader senotherapeutics market against companies developing senolytics (e.g., Unity Biotechnology) and senomorphics. Its key differentiation is its focus on reversing senescence via RNA splicing modulation, a mechanism distinct from most competitors. However, it must demonstrate superior efficacy or safety to gain traction.